title: Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials.
abstract: There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with risperidone. Study 1 included 52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions. Study 2 included 49 subjects assigned to risperidone only and 75 subjects assigned to risperidone plus parent training. After 8 weeks of treatment, all active treatments were superior to placebo (effect sizes ranging from 0.42 to 0.65). The findings suggest that the Social Withdrawal subscale may be a useful measure of social disability in acute treatment trials.
authors.affiliation: Yale University School of Nursing and Child Study Center, New Haven, CT, USA. lawrence.scahill@emory.edu
authors.forename: Lawrence
authors.initials: L
authors.lastname: Scahill
authors.forename: Victoria
authors.initials: V
authors.lastname: Hallett
authors.forename: Michael G
authors.initials: MG
authors.lastname: Aman
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: McDougle
authors.forename: L
authors.initials: L
authors.lastname: Eugene Arnold
authors.forename: James T
authors.initials: JT
authors.lastname: McCracken
authors.forename: Elaine
authors.initials: E
authors.lastname: Tierney
authors.forename: Yanhong
authors.initials: Y
authors.lastname: Deng
authors.forename: James
authors.initials: J
authors.lastname: Dziura
authors.forename: Benedetto
authors.initials: B
authors.lastname: Vitiello
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000188:drug therapy / Q000523:psychology*; D002675:Child, Preschool; D004311:Double-Blind Method; D006801:Humans; D011569:Psychiatric Status Rating Scales; D012107:Research Design; D018967:Risperidone / Q000627:therapeutic use; D012919:Social Behavior; D012938:Social Perception; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D018967:Risperidone